Myorel 50 mg Capsule is a Health Canada–registered human drug (DIN 02240324) held by Thorne Research Canada Ltd., containing Cimicifuga Racemosa. Health Canada lists its status as Cancelled (Unreturned Annual) (status date 23 Mar 2018). Nexara Health has matched 14 registrations of Cimicifuga Racemosa across 2 other regulated markets.
Health Canada registration
| DIN | 02240324 |
|---|---|
| Brand name | Myorel |
| Active ingredient | Cimicifuga Racemosa |
| Strength | 50 mg |
| Dosage form | Capsule |
| Route | Oral |
| Company | Thorne Research Canada Ltd. |
| Status | Cancelled (Unreturned Annual) — 23 Mar 2018 |
| Class | Human |
| ATC | |
| AHFS | 38:00.00 |
| Regulator record | Health Canada DPD entry · Product monograph |
Cimicifuga Racemosa registered in other markets
14 registrations of the same molecule in 2 national registries outside Canada (first 10 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Netherlands | Cimicifuga racemosa | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Globuli | Uitsluitend apotheek of drogist | EU national register |
| Netherlands | Cimicifuga racemosa | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Uitsluitend apotheek of drogist | EU national register | |
| United States | Bestmade Natural Products Cimicifuga Racemosa | Bestmade Natural Products | Tablet, Soluble | listed | FDA NDC | |
| United States | BM Cimicifuga Racemosa | BM Private Limited | Globule | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Cimicifuga Racemosa | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC |
See every manufacturer of Cimicifuga Racemosa worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Myorel (DIN 02240324) marketed in Canada?
No. Health Canada lists DIN 02240324 as Cancelled (Unreturned Annual) as of 23 Mar 2018.
Who holds the Canadian licence for this product?
Thorne Research Canada Ltd. is the company of record in the Health Canada Drug Product Database.
Is Cimicifuga Racemosa registered outside Canada?
Yes — Nexara Health has matched 14 registrations in 2 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02240324, status date 2018-03-23; national medicine registries: EU national register, FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02240324, status date 2018-03-23; national medicine registries: EU national register, FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02240324, status date 2018-03-23; national medicine registries: EU national register, FDA NDC. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.